AIFF News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

AI

Mkt Cap

$16.0M

Volume

118.24K

Next Earnings

November 11th

Loading chart

AI

AIFFFirefly Neuroscience, Inc. Common Stock

AIFF

Pay with—

Available Balance0.00

AI

Mkt Cap

$17.3M

Volume

118.24K

Next Earnings

November 11th

Chart Financials Earnings News About Insider Filings

Firefly Neuroscience (NASDAQ: AIFF) Reports 291% Increase in TMS Center Customer Brain Scan VolumesFirefly Neuroscience announced a nearly four-fold increase in TMS center customer clinical assessments using its FDA-cleared Evoke AI-powered EEG/ERP platform. The platform combines quantitative EEG and event-related potentials to help clinicians assess brain activity and tailor treatments for psychiatric and behavioral health conditions. The company continues to expand adoption among TMS centers while building its proprietary database of over 200,000 EEG/ERP brain scans.GlobeNewswire Inc. · Aug 5, 2026

Firefly Neuroscience (NASDAQ: AIFF) and Next Health Launch Precision Cognitive Health Initiative as FDA Advisory Committee’s Recommendation Backs Broader Access to Key Neuroprotective PeptidesFirefly Neuroscience (NASDAQ: AIFF) and Next Health announced a strategic partnership to launch a precision cognitive health platform combining Firefly's FDA-cleared AI-powered EEG/ERP brain biomarker technology with personalized cognitive peptide protocols. The collaboration follows an FDA Advisory Committee's recommendation to ease compounding restrictions for six peptides, including Epitalon and Semax, which have shown potential neuroprotective and cognitive-supportive properties in scientific literature.GlobeNewswire Inc. · Jul 28, 2026

Firefly Neuroscience Researchers Uncover Powerful New Way of Objectively Measuring SCD, MCI, and Dementia in Alzheimer’s PatientsFirefly Neuroscience researchers have developed a new method to accurately differentiate between subjective cognitive decline (SCD), mild cognitive impairment (MCI), and dementia in Alzheimer's patients using a combination of EEG/ERP and volumetric MRI data.GlobeNewswire Inc. · Jun 20, 2025

Firefly Neuroscience Achieves Multi-Fold Database, IP Portfolio, and Commercial Footprint Expansion Through Acquisition of Evoke Neuroscience, Inc.Firefly Neuroscience, an AI company, has acquired Evoke Neuroscience, a medical device company, to expand its proprietary database, patent portfolio, and commercial reach. The acquisition marks a significant step towards Firefly's goal of building a foundation model of the human brain.Benzinga · May 5, 2025

Firefly Neuroscience Announces Exercise of Warrants for Total Proceeds of $8.8 MillionFirefly Neuroscience, Inc. has received $8.8 million from the exercise of warrants, which will be used for general working capital purposes, including the development of its FDA-cleared Brain Network Analytics (BNA™) technology platform.GlobeNewswire Inc. · Feb 21, 2025

Firefly Neuroscience Accepted into NVIDIA Connect ProgramFirefly Neuroscience, an AI company developing solutions for brain health, has been accepted into the NVIDIA Connect program. This will provide Firefly with technical resources to support its initiative to build a proprietary foundation model of the human brain using its FDA-cleared BNA™ technology platform.GlobeNewswire Inc. · Feb 11, 2025

Firefly Neuroscience Reports Third Quarter 2024 Results and Provides Stockholder UpdateFirefly Neuroscience, a Nasdaq-listed AI company, announced its Q3 2024 financial results and provided updates on its partnerships with pharmaceutical companies like Bright Minds Bioscience, Novartis, and Takeda to advance its Brain Network Analytics (BNA) technology for neurological and mental disorder treatments.GlobeNewswire Inc. · Nov 14, 2024

4 Biotech Stocks With AI, Machine Learning ProwessThe article discusses four biotech companies leveraging AI and machine learning technology to improve drug discovery and development processes. These companies are Absci, Firefly Neuroscience, Korro Bio, and NeuroSense Therapeutics.Investing.com · Nov 8, 2024

Firefly Neuroscience CEO Jon Olsen to Present at H.C. Wainwright’s 26th Annual Global Investment Conference September 9-11Firefly Neuroscience, an AI company developing solutions to improve brain health, announced that its CEO will present at an investment conference. The company's FDA-cleared Brain Network Analytics (BNA) platform aims to enhance diagnosis and treatment monitoring for various neurological and mental disorders.GlobeNewswire Inc. · Aug 26, 2024

Firefly Neuroscience Forms Strategic Partnership with Neurology Consultants of Dallas (NCD) to Enhance Early Detection Efforts and Disease Management for Patients with Cognitive DisordersFirefly Neuroscience and Neurology Consultants of Dallas (NCD) have formed a strategic partnership to integrate Firefly's Brain Network Analytics (BNA) technology into NCD's patient management protocols, aiming to enhance early detection and disease management for patients with cognitive disorders.GlobeNewswire Inc. · Aug 21, 2024

to start trading

AI

AIFFFirefly Neuroscience, Inc. Common Stock

AIFF

Pay with—

Available Balance0.00

Your PositionYou don't own any AIFF yet.

Related Tickers

Earnings